MK-677 5 mg — Growth Hormone & Metabolic Research
MK-677 is commonly used to refer to ibutamoren (MK-677), a non-peptide ghrelin-receptor agonist and growth-hormone secretagogue. It is studied for its effects on the growth hormone (GH)/IGF-1 axis, appetite signaling, energy metabolism, body composition, sleep physiology, and mechanisms involved in muscle and bone metabolism.
Research investigates how activation of the ghrelin receptor (GHS-R1a) influences endocrine and metabolic pathways, including changes in GH and IGF-1 signaling.
For laboratory and research use only. Not for human consumption.
MK-677 5 mg — Growth Hormone & Metabolic Research
MK-677 is commonly used to refer to ibutamoren (MK-677), a non-peptide ghrelin-receptor agonist and growth-hormone secretagogue. It is studied for its effects on the growth hormone (GH)/IGF-1 axis, appetite signaling, energy metabolism, body composition, sleep physiology, and mechanisms involved in muscle and bone metabolism.
Research investigates how activation of the ghrelin receptor (GHS-R1a) influences endocrine and metabolic pathways, including changes in GH and IGF-1 signaling.
For laboratory and research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
